(Q40938782)

25 September 2017

1 reference

title

The basis of current and future therapy for inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

25 September 2017

main subject

1 reference

Elson CO

1

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 June 1996

1 reference

American Journal of Medicine

25 September 2017

published in

1 reference

25 September 2017

volume

100

1 reference

25 September 2017

issue

6

1 reference

25 September 2017

page(s)

656-662

1 reference

Advances in drug therapy for inflammatory bowel disease

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

An experiment to determine the active therapeutic moiety of sulphasalazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

Methotrexate for the Treatment of Crohn's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

The effect of immunosuppressive agents on monocyte generation and cytokine expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

Experimental models of inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

T cells in inflammatory bowel disease: protective and pathogenic roles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900049-6

10.1016/S0002-9343(96)00049-6

7 January 2021

Identifiers

DOI

1 reference

25 September 2017

1 reference